A trial of oats in children with newly diagnosed celiac disease

J Pediatr. 2000 Sep;137(3):361-6. doi: 10.1067/mpd.2000.109003.

Abstract

Objective: To determine whether consumption of oats is safe in children with newly diagnosed celiac disease who are starting a gluten-free diet.

Study design: We conducted a self-controlled, open-label, 6-month trial of a commercial oat breakfast cereal product. Primary outcome variables were small bowel histomorphology and anti-tissue transglutaminase IgA antibody titer.

Results: The 10 children who completed the study were 6.8 +/- 4.0 (mean +/- SD) years of age and 5 were male. Over 6.6 +/- 0.7 months, they consumed 24 grams of oat cereal per day, or 1.2 +/- 0.9 g/kg/d. Compared with start of study, at completion there was a significant decrease in biopsy score (P <.01), intra-epithelial lymphocyte count (P <.005), anti-tissue transglutaminase IgA antibody titer (P <.01), and number of symptoms (P <.01).

Conclusions: We conclude that consumption of a commercially available oat cereal product for 6 months is safe for children with celiac disease beginning a gluten-free diet. Studies are needed to determine the long-term safety of including oat cereal in the gluten-free diet.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Avena*
  • Celiac Disease / diagnosis
  • Celiac Disease / diet therapy*
  • Celiac Disease / immunology
  • Celiac Disease / pathology
  • Child
  • Female
  • Glutens
  • Humans
  • Immunoglobulin A / analysis
  • Intestine, Small / enzymology
  • Intestine, Small / immunology
  • Intestine, Small / pathology
  • Lymphocyte Count
  • Male
  • Radioimmunoassay
  • Statistics, Nonparametric
  • Transglutaminases / immunology

Substances

  • Immunoglobulin A
  • Glutens
  • Transglutaminases